Tolprist ET Tablet, with its powerful combination of Tolperisone (150mg) and Etoricoxib (90mg), represents a cutting-edge solution for the comprehensive management of musculoskeletal pain and associated muscle spasms. Tolperisone acts as a centrally acting muscle relaxant, effectively reducing muscle stiffness and improving mobility without causing sedation. Etoricoxib, a potent selective COX-2 inhibitor, provides powerful anti-inflammatory and analgesic effects. This synergistic formulation offers dual-action relief, addressing both the source of the pain and the involuntary muscle contractions, making it an essential prescription for conditions like acute lower back pain, cervical spondylitis, and post-operative discomfort.
The orthopedics and pain management segments of the Indian pharmaceutical market are experiencing consistent growth, driven by an increasing prevalence of lifestyle-related disorders, injuries, and an aging population. This creates a stable and high-demand environment for a product like Tolprist ET Tablet. A PCD pharma franchise for this product allows you to capitalize on this resilient market. We offer a monopoly-based business model in your designated territory, protecting your business from internal competition and helping you build a dominant position in the B2B supply chain for orthopedics clinics, hospitals, and pharmacies.
We are dedicated to empowering our franchise partners with all the tools necessary for success. Our product, manufactured in a WHO-GMP certified facility, ensures impeccable quality, efficacy, and safety, building trust with healthcare professionals. We provide a complete promotional and marketing kit, including product literature and visual aids, to support your sales efforts. Our robust supply chain guarantees timely delivery and continuous stock availability, preventing any business interruptions. Partner with us to enter this stable and highly profitable market and establish a reputable and successful business as a key supplier of an essential medication.